Search

Your search keyword '"Ohman, E. Magnus"' showing total 128 results
Start Over Author "Ohman, E. Magnus" Publication Year Range Last 3 years
128 results on '"Ohman, E. Magnus"'

1. Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial

Author

Nakamura, Kenta, Henry, Timothy D., Traverse, Jay H., Latter, David A., Mokadam, Nahush A., Answini, Geoffrey A., Williams, Adam R., Sun, Benjamin C., Burke, Christopher R., Bakaeen, Faisal G., DiCarli, Marcelo F., Chaitman, Bernard R., Peterson, Mark W., Byrnes, Dawn G., Ohman, E. Magnus, Pepine, Carl J., Crystal, Ronald G., Rosengart, Todd K., Kowalewski, Elaine, Koch, Gary G., Dittrich, Howard C., and Povsic, Thomas J.

Published
2024
Full Text
View/download PDF

3. Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y12 Inhibitor Therapy: The CAMEO Registry

Author

Rymer, Jennifer, Alhanti, Brooke, Kemp, Steven, Bhatt, Deepak L., Kochar, Ajar, Angiolillo, Dominick J., Diaz, Miguel, Garratt, Kirk N., Wimmer, Neil J., Waksman, Ron, Kirtane, Ajay J., Ang, Lawrence, Bach, Richard, Barker, Colin, Jenkins, Ronald, Basir, Mir B., Sullivan, Alex, El-Sabae, Hijrah, Brothers, Leo, Ohman, E. Magnus, Jones, W. Schuyler, Washam, Jeffrey B., and Wang, Tracy Y.

Published
2024
Full Text
View/download PDF

5. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

Author

Angiolillo, Dominick J., Cao, Davide, Sartori, Samantha, Baber, Usman, Dangas, George, Zhang, Zhongjie, Vogel, Birgit, Kunadian, Vijay, Briguori, Carlo, Cohen, David J., Collier, Timothy, Dudek, Dariusz, Gibson, Michael, Gil, Robert, Huber, Kurt, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell W., Ielasi, Alfonso, Stefanini, Giulio G., Pivato, Carlo A., Mehta, Shamir, Moliterno, David J., Ohman, E. Magnus, Escaned, Javier, Sardella, Gennaro, Sharma, Samin K., Shlofmitz, Richard, Weisz, Giora, Witzenbichler, Bernhard, Steg, P. Gabriel, Pocock, Stuart, and Mehran, Roxana

Published
2023
Full Text
View/download PDF

6. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

Author

Mendieta, Guiomar, Mehta, Shamir, Baber, Usman, Angiolillo, Dominick J., Briguori, Carlo, Cohen, David, Collier, Timothy, Dangas, George, Dudek, Dariusz, Escaned, Javier, Gil, Robert, Vogel, Birgit, Cao, Davide, Spirito, Alessandro, Huber, Kurt, Kastrati, Adnan, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell W., Kunadian, Vijay, Moliterno, David J., Ohman, E. Magnus, Sardella, Gennaro, Sartori, Samantha, Sharma, Samin, Shlofmitz, Richard, Steg, P. Gabriel, Han, Ya-Ling, Pocock, Stuart, Gibson, C. Michael, and Mehran, Roxana

Published
2023
Full Text
View/download PDF

7. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry

Author

Abtan, Jeremie, Bhatt, Deepak L., Elbez, Yedid, Ducrocq, Gregory, Goto, Shinya, Smith, Sidney C., Jr, Ohman, E. Magnus, Eagle, Kim A., Fox, Kim, Harrington, Robert A., Leiter, Lawrence A., Mehta, Shamir R., Simon, Tabassome, Petrov, Ivo, Sinnaeve, Peter R., Pais, Prem, Lev, Eli, Bueno, Héctor, Wilson, Peter, and Steg, Philippe Gabriel

Published
2023
Full Text
View/download PDF

8. EXACT Trial: Results of the Phase 1 Dose-Escalation Study

Author

Povsic, Thomas J., Henry, Timothy D., Traverse, Jay H., Anderson, R. David, Answini, Geoffrey A., Sun, Benjamin C., Arnaoutakis, George J., Boudoulas, Konstantinos D., Williams, Adam R., Dittrich, Howard C., Tarka, Elizabeth A., Latter, David A., Ohman, E. Magnus, Peterson, Mark W., Byrnes, Dawn, Pepine, Carl J., DiCarli, Marcelo F., Crystal, Ronald G., Rosengart, Todd K., and Mokadam, Nahush A.

Published
2023
Full Text
View/download PDF

10. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose

Author

Gibson, C. Michael, Mack, Michael J., Lee, Victoria T., Schneider, David J., Sellke, Frank W., Ohman, E. Magnus, Thourani, Vinod H., Doros, Gheorghe, Kroger, Hans, Cutlip, Donald E., and Deliargyris, Efthymios N.

Published
2022
Full Text
View/download PDF

14. Timing of sedation and patient‐reported pain outcomes during cardiac catheterization: Results from the UNTAP‐intervention study

Author

Mall, Anna, primary, Girton, T. Andrew, additional, Yardley, Kevin, additional, Ronn, Meghan, additional, Cross, Elinore, additional, Smith, Patrick J., additional, Rossman, Paige, additional, McEwen, Tiffany, additional, Ohman, E. Magnus, additional, Jones, W. Schuyler, additional, and Granger, Bradi B., additional

Published
2023
Full Text
View/download PDF

15. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study

Author

Dangas, George, Baber, Usman, Sharma, Samin, Giustino, Gennaro, Sartori, Samantha, Nicolas, Johny, Goel, Ridhima, Mehta, Shamir, Cohen, David J., Angiolillo, Dominick J., Zhang, Zhongjie, Camaj, Anton, Cao, Davide, Briguori, Carlo, Dudek, Dariusz, Escaned, Javier, Huber, Kurt, Collier, Timothy, Kornowski, Ran, Kunadian, Vijay, Moliterno, David J., Ohman, E. Magnus, Weisz, Giora, Gil, Robert, Krucoff, Mitchell W., Kaul, Upendra, Oldroyd, Keith G., Sardella, Gennaro, Shlofmitz, Richard, Witzenbichler, Bernhard, Kastrati, Adnan, Han, Ya-ling, Steg, Philippe Gabriel, Pocock, Stuart, Gibson, C. Michael, and Mehran, Roxana

Subjects
Ticagrelor, Percutaneous Coronary Intervention, Treatment Outcome, Clinical Research, Humans, Drug-Eluting Stents, Stents, Everolimus, Cardiology and Cardiovascular Medicine, Platelet Aggregation Inhibitors
Abstract

BACKGROUND: In the TWILIGHT trial, ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) was shown to be a safe bleeding avoidance strategy in high-risk patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). AIMS: The aim of this study was to evaluate the effects of ticagrelor monotherapy after three-month DAPT in patients undergoing PCI, according to DES type. METHODS: In the current sub-analysis from TWILIGHT, patients were stratified into three groups based on DES type: durable polymer everolimus-eluting stents (DP-EES), durable polymer zotarolimus-eluting stents (DP-ZES), and biodegradable polymer DES (BP-DES). Bleeding and ischaemic outcomes were assessed at one year after randomisation. RESULTS: Out of 5,769 patients, 3,014 (52.2%) had DP-EES, 1,350 (23.4%) had DP-ZES and 1,405 (24.4%) had BP-DES. Compared with ticagrelor plus aspirin, ticagrelor monotherapy had significantly lower BARC type 2, 3 or 5 bleeding compared with DAPT; DP-EES (3.8% vs 6.7%; HR 0.56, 95% CI: 0.41-0.78), DP-ZES (4.6% vs 6.9%; HR 0.66, 95% CI: 0.42-1.04) and BP-DES (4.2% vs 7.9%; HR 0.52, 95% CI: 0.33-0.81; p(interaction)=0.76). Ticagrelor monotherapy resulted in similar rates of death, MI, or stroke: DP-EES (4.2% vs 4.3%; HR 0.97; 95% CI: 0.68-1.37); DP-ZES (4.1% vs 3.1%; HR 1.32; 95% CI: 0.75-2.33); BP-DES (3.9% vs 4.2%; HR 0.92; 95% CI: 0.54-1.55; p(interaction)=0.60). In both unadjusted and covariate-adjusted analyses, DES type was not associated with any differences in ischaemic or bleeding complications. CONCLUSIONS: As compared with ticagrelor plus aspirin, ticagrelor monotherapy after a short DAPT duration lowered bleeding complications without increasing the ischaemic risk, irrespective of DES type. We observed no significant differences among DES types.

Published
2022

16. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study

Author

Sardella, Gennaro, primary, Beerkens, Frans J., additional, Dangas, George, additional, Cao, Davide, additional, Baber, Usman, additional, Sartori, Samantha, additional, Cohen, David J., additional, Briguori, Carlo, additional, Gil, Robert, additional, Nicolas, Johny, additional, Zhang, Zhongjie, additional, Dudek, Dariusz, additional, Kunadian, Vijay, additional, Kornowski, Ran, additional, Weisz, Giora, additional, Claessen, Bimmer, additional, Marx, Steven, additional, Escaned, Javier, additional, Huber, Kurt, additional, Collier, Timothy, additional, Moliterno, David J., additional, Ohman, E. Magnus, additional, Krucoff, Mitchell W., additional, Kastrati, Adnan, additional, Steg, Phillipe Gabriel, additional, Angiolillo, Dominick J., additional, Mehta, Shamir, additional, Shlofmitz, Richard, additional, Sharma, Samin, additional, Pocock, Stuart, additional, Gibson, Charles Michael, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

18. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index

Author

Kunadian, Vijay, primary, Baber, Usman, additional, Pivato, Carlo A., additional, Cao, Davide, additional, Dangas, George, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Angiolillo, Dominick J., additional, Briguori, Carlo, additional, Cohen, David J., additional, Collier, Timothy, additional, Dudek, Dariusz, additional, Gibson, Michael, additional, Gil, Robert, additional, Huber, Kurt, additional, Kaul, Upendra, additional, Kornowski, Ran, additional, Krucoff, Mitchell W., additional, Dehghani, Payam, additional, Mehta, Shamir, additional, Moliterno, David J., additional, Ohman, E. Magnus, additional, Escaned, Javier, additional, Sardella, Gennaro, additional, Sharma, Samin K., additional, Shlofmitz, Richard, additional, Weisz, Giora, additional, Witzenbichler, Bernhard, additional, Džavík, Vladimír, additional, Gurbel, Paul, additional, Hamm, Christian W., additional, Henry, Timothy, additional, Kastrati, Adnan, additional, Marx, Steven O., additional, Oldroyd, Keith, additional, Steg, P. Gabriel, additional, Pocock, Stuart, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

20. Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials)

Author

Attar, Rubina, primary, Wu, Angie, additional, Wojdyla, Daniel, additional, Jensen, Svend Eggert, additional, Andell, Pontus, additional, Mahaffey, Kenneth W., additional, Roe, Matthew T., additional, James, Stefan K., additional, Wallentin, Lars, additional, Vemulapalli, Sreekanth, additional, Alexander, John H., additional, Lopes, Renato D., additional, Ohman, E. Magnus, additional, Hernandez, Adrian F., additional, Patel, Manesh R., additional, and Jones, W. Schuyler, additional

Published
2022
Full Text
View/download PDF

21. TCT-13 Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI

Author

Spirito, Alessandro, primary, Cao, Davide, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Nicolas, Johny, additional, Cohen, David, additional, Angiolillo, Dominick, additional, Briguori, Carlo, additional, Vogel, Birgit, additional, Collier, Timothy, additional, Dudek, Dariusz, additional, Escaned, Javier, additional, Sharma, Samin, additional, Farhan, Serdar, additional, Huber, Kurt, additional, Kastrati, Adnan, additional, Kornowski, Ran, additional, Krucoff, Mitchell, additional, Kunadian, Vijay, additional, Mehta, Shamir, additional, Moliterno, David, additional, Ohman, E. Magnus, additional, Sardella, Gennaro, additional, Shlofmitz, Richard, additional, Steg, Philippe, additional, Witzenbichler, Bernhard, additional, Han, Yaling, additional, Pocock, Stuart, additional, Dangas, George, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

23. Impella Mechanical Circulatory Support for Takotsubo Syndrome With Shock: A Retrospective Multicenter Analysis

Author

Napp, L. Christian, primary, Westenfeld, Ralf, additional, Møller, Jacob E., additional, Pappalardo, Federico, additional, Ibrahim, Karim, additional, Bonello, Laurent, additional, Wilkins, Charles, additional, Pershad, Ashish, additional, Mannino, Salvatore F., additional, Schreiber, Theodore L., additional, Hall, Patrick A., additional, Medjamia, Amin M., additional, Haurand, Jean M., additional, Sieweke, Jan-Thorben, additional, Schäfer, Andreas, additional, Grines, Cindy L., additional, Burkhoff, Daniel, additional, Moses, Jeffrey W., additional, Ohman, E. Magnus, additional, O'Neill, William W., additional, Kapur, Navin K., additional, and Bauersachs, Johann, additional

Published
2022
Full Text
View/download PDF

24. Cangrelor Use Patterns and Transition to Oral P2Y 12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry

Author

Rymer, Jennifer A., primary, Bhatt, Deepak L., additional, Angiolillo, Dominick J., additional, Diaz, Miguel, additional, Garratt, Kirk N., additional, Waksman, Ron, additional, Edwards, Laura, additional, Tasissa, Gudaye, additional, Salahuddin, Khalid, additional, El‐Sabae, Hijrah, additional, Dell’Anna, Carmen, additional, Davidson‐Ray, Linda, additional, Washam, Jeffrey B., additional, Ohman, E. Magnus, additional, and Wang, Tracy Y., additional

Published
2022
Full Text
View/download PDF

25. Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors

Author

Figtree, Gemma A., primary, Redfors, Bjorn, additional, Kozor, Rebecca, additional, Vernon, Stephen T., additional, Grieve, Stuart M., additional, Mazhar, Jawad, additional, Thiele, Holger, additional, Patel, Manesh R., additional, Udelson, James E., additional, Selker, Harry P., additional, Ohman, E. Magnus, additional, Maehara, Akiko, additional, Karmpaliotis, Dmitri, additional, Eitel, Ingo, additional, Granger, Christopher B., additional, Ben-Yehuda, Ori, additional, Stone, Gregg W., additional, and Kosmidou, Ioanna, additional

Published
2022
Full Text
View/download PDF

27. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy

Author

Han, Yaling, primary, Claessen, Bimmer E., additional, Chen, Shao-Liang, additional, Chunguang, Qiu, additional, Zhou, Yujie, additional, Xu, Yawei, additional, Hailong, Lin, additional, Chen, Jiyan, additional, Qiang, Wu, additional, Zhang, Ruiyan, additional, Luo, Suxin, additional, Li, Yongjun, additional, Zhu, Jianhua, additional, Zhao, Xianxian, additional, Cheng, Xiang, additional, Wang, Jian’an, additional, Su, Xi, additional, Tao, Jianhong, additional, Sun, Yingxian, additional, Wang, Geng, additional, Li, Yi, additional, Bian, Liya, additional, Goel, Ridhima, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Angiolillo, Dominick J., additional, Cohen, David J., additional, Gibson, C. Michael, additional, Kastrati, Adnan, additional, Krucoff, Mitchell, additional, Mehta, Shamir R., additional, Ohman, E. Magnus, additional, Steg, Philippe Gabriel, additional, Liu, Yuqi, additional, Dangas, George, additional, Sharma, Samin, additional, Baber, Usman, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

28. Ticagrelor monotherapy after PCI in high-risk patients with prior MI : A prespecified TWILIGHT Substudy

Author

Chiarito, Mauro, Baber, Usman, Cao, Davide, Sharma, Samin K., Dangas, George, Angiolillo, Dominick J., Briguori, Carlo, Cohen, David J., Dudek, Dariusz, Džavík, Vladimír, Escaned, Javier, Gil, Robert, Hamm, Christian W., Henry, Timothy, Huber, Kurt, Kastrati, Adnan, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell, Kunadian, Vijay, Mehta, Shamir R., Moliterno, David, Ohman, E. Magnus, Oldroyd, Keith, Sardella, Gennaro, Zhongjie, Zhang, Sartori, Samantha, Stefanini, Giulio, Shlofmitz, Richard, Steg, P. Gabriel, Weisz, Giora, Witzenbichler, Bernhard, Han, Ya-Ling, Pocock, Stuart, Gibson, C. Michael, and Mehran, Roxana

Published
2022

29. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD

Author

Dehghani, Payam, primary, Cao, Davide, additional, Baber, Usman, additional, Nicolas, Johny, additional, Sartori, Samantha, additional, Pivato, Carlo A, additional, Zhang, Zhongjie, additional, Dangas, George, additional, Angiolillo, Dominick J, additional, Briguori, Carlo, additional, Cohen, David J, additional, Collier, Timothy, additional, Dudek, Dariusz, additional, Gibson, Michael, additional, Gil, Robert, additional, Huber, Kurt, additional, Kaul, Upendra, additional, Kornowski, Ran, additional, Krucoff, Mitchell W, additional, Kunadian, Vijay, additional, Mehta, Shamir, additional, Moliterno, David J, additional, Ohman, E Magnus, additional, Escaned, Javier, additional, Sardella, Gennaro, additional, Sharma, Samin K, additional, Shlofmitz, Richard, additional, Weisz, Giora, additional, Witzenbichler, Bernhard, additional, Pocock, Stuart, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

31. TICAGRELOR MONOTHERAPY AFTER PCI ACROSS THE SPECTRUM OF HIGH-RISK PATIENTS: A DEEP DIVE INTO THE TWILIGHT TRIAL

Author

Nicolas, Johny, primary, Steg, Philippe Gabriel, additional, Cao, Davide, additional, Baber, Usman, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Sharma, Samin K., additional, Cohen, David J., additional, Angiolillo, Dominick J., additional, Collier, Tim, additional, Escaned, Javier, additional, Gil, Robert, additional, Beerkens, Frans, additional, Džavík, Vladimír, additional, Henry, Timothy D., additional, Huber, Kurt, additional, Kornowski, Ran, additional, Ohman, E Magnus, additional, Krucoff, Mitchell W., additional, Kunadian, Vijay, additional, Pocock, Stuart J., additional, Gibson, Charles Michael, additional, Dangas, George D., additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

33. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI

Author

Chiarito, Mauro, primary, Baber, Usman, additional, Cao, Davide, additional, Sharma, Samin K., additional, Dangas, George, additional, Angiolillo, Dominick J., additional, Briguori, Carlo, additional, Cohen, David J., additional, Dudek, Dariusz, additional, Džavík, Vladimír, additional, Escaned, Javier, additional, Gil, Robert, additional, Hamm, Christian W., additional, Henry, Timothy, additional, Huber, Kurt, additional, Kastrati, Adnan, additional, Kaul, Upendra, additional, Kornowski, Ran, additional, Krucoff, Mitchell, additional, Kunadian, Vijay, additional, Mehta, Shamir R., additional, Moliterno, David, additional, Ohman, E. Magnus, additional, Oldroyd, Keith, additional, Sardella, Gennaro, additional, Zhongjie, Zhang, additional, Sartori, Samantha, additional, Stefanini, Giulio, additional, Shlofmitz, Richard, additional, Steg, P. Gabriel, additional, Weisz, Giora, additional, Witzenbichler, Bernhard, additional, Han, Ya-ling, additional, Pocock, Stuart, additional, Gibson, C. Michael, additional, and Mehran, Roxana, additional

Published
2022
Full Text
View/download PDF

34. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

Author

Cavender, Matthew A., primary, Harrington, Robert A., additional, Stone, Gregg W., additional, Steg, Ph. Gabriel, additional, Gibson, C. Michael, additional, Hamm, Christian W., additional, Price, Matthew J., additional, Lopes, Renato D., additional, Leonardi, Sergio, additional, Deliargyris, Efthymios N., additional, Prats, Jayne, additional, Mahaffey, Kenneth W., additional, White, Harvey D., additional, Bhatt, Deepak L., additional, Huber, Kurt, additional, Lima, Valter C., additional, Jorgova-Makedonska, Julia B., additional, Widimský, Petr, additional, Kobulia, Bondo, additional, Radke, Peter W., additional, Bramucci, Ezio, additional, Witkowski, Adam, additional, Shlyakhto, Evgeny, additional, Van de Werf, Frans, additional, Faxon, David P., additional, Ohman, E. Magnus, additional, Verheugt, Freek W.A., additional, Weaver, W. Douglas, additional, Tijssen, Jan G.P., additional, Wilson, Matthew, additional, Mangum, Stacey, additional, Melloni, Chiara, additional, Brennan, Matthew J., additional, Tricoci, Pierluigi, additional, Harrison, Robert, additional, Barros, Pedro, additional, Armaganijan, Luciana, additional, Anderson, Monique, additional, Bagai, Akshay, additional, Généreux, Philippe, additional, Brener, Sorin J., additional, LaSalle, Laura, additional, Benzer, Werner, additional, Delle-Karth, Georg, additional, Leisch, Franz, additional, Abdalla Saad, Jamil, additional, Abizaid, Alexandre, additional, Augusto Formiga Areas, Carlos, additional, Ribeiro, Expedito E., additional, Rossi Dos Santos, Fabio, additional, Tadeu Tumelero, Rogerio, additional, Vieira Botelho, Roberto, additional, Atzev, Borislav, additional, Boichev, Boicho, additional, Grigorov, Georgi, additional, Penkov, Nikolay, additional, Petrov, Ivo, additional, Zehirov, Boris, additional, Cervinka, Pavel, additional, Coufal, Zdenek, additional, Hajek, Petr, additional, Horak, David, additional, Kala, Petr, additional, Kmonicek, Petr, additional, Kocka, Viktor, additional, Mrozek, Jan, additional, Simek, Stanislav, additional, Sitar, Jan, additional, Stasek, Josef, additional, Tousek, Frantisek, additional, Chapidze, Gulnara, additional, Emukhvari, Nodar, additional, Khabeishvili, George, additional, Mamatsashvili, Merab, additional, Shaburishvili, Tamaz, additional, Behrens, Steffen, additional, Darius, Harald, additional, Dissmann, Martin, additional, Fichtlscherer, Stephan, additional, Franz, Wolfgang, additional, Geisler, Tobias, additional, Genth-Zotz, Sabine, additional, Goldmann, Britta, additional, Heuer, Hubertus, additional, Hoffmann, Stefan, additional, Mugge, Andreas, additional, Poerner, Tudor, additional, Radke, Peter, additional, Richardt, Gert, additional, Stellbrink, Christoph, additional, Werner, Nikos, additional, De Servi, Stefano, additional, Galasso, Gennaro, additional, Menozzi, Alberto, additional, Musumeci, Giuseppe, additional, Picchi, Andrea, additional, Presbitero, Patrizia, additional, Devlin, Gerard, additional, Sasse, Alexander, additional, Scott, Douglas, additional, Stewart, Ralph, additional, Andrzej, Szyszka, additional, Dubaniewicz, Witold, additional, Gasior, Zbigniew, additional, Kasprzak, Jaroslaw, additional, Kleinrok, Andrzej, additional, Kornacewicz-Jach, Zdzislawa, additional, Rynkiewicz, Andrzej, additional, Sosnowski, Cezary, additional, Targonski, Radoslaw, additional, Trebacz, Jaroslaw, additional, Zinka, Elzbieta, additional, Barbarash, Olga, additional, Dovgalevsky, Yakov, additional, Gordeev, Ivan, additional, Kalinina, Svetlana, additional, Kosmachova, Elena, additional, Markov, Valentin, additional, Pavlov, Prokhor, additional, Shalaev, Sergey, additional, Shogenov, Zaur, additional, Sukmanova, Irina, additional, Vasilieva, Elena, additional, Yakovlev, Alexey, additional, Boonbaichaiyapruck, Sarana, additional, Chamnarnphol, Noppadol, additional, Kaewsuwanna, Pinij, additional, Kuanprasert, Srun, additional, Piyayotai, Dilok, additional, Amine, Maged, additional, Angiolillo, Dominick, additional, Arif, Imran, additional, Blankenship, James, additional, Brilakis, Emmanouil, additional, Chan, Michael, additional, Cinderella, Joseph, additional, Davis, Brent, additional, Devireddy, Chandanreddy, additional, Dorogy, Mark, additional, Douglas, John, additional, Ferrier, Norman, additional, Fisher, Daniel, additional, Foster, Robert, additional, French, William, additional, Galla, John, additional, Gimple, Lawrence, additional, Gogia, Harinder, additional, Gogo, Prospero, additional, Gollapudi, Raghava, additional, Gruberg, Luis, additional, Hermiller, James, additional, Heuser, Richard, additional, Iwaoka, Robert, additional, Jafar, Zubair, additional, Kimmelstiel, Carey, additional, Kinlay, Scott, additional, Leggett, James, additional, Leimgruber, Pierre, additional, Letts, Dustin, additional, Lipsitt, Michael, additional, Low, Reginald, additional, Martinez-Arraras, Joaquin, additional, Mayhew, Marc, additional, McLaurin, Brent, additional, McWhirter, Paul, additional, Mirza, Ayoub, additional, Negus, Brian, additional, Nygaard, Thomas, additional, O’Riordan, William, additional, Paulus, Richard, additional, Petersen, John, additional, Picon, Hector, additional, Picone, Mark, additional, Rivera, Ernesto, additional, Rizik, David, additional, Rodriguez, Arsenio, additional, Saucedo, Jorge, additional, Scott, J. Christopher, additional, Sethi, Virender, additional, Shroff, Adhir, additional, Siegel, Craig, additional, Spriggs, Douglas, additional, Steinberg, Daniel, additional, Stillabower, Michael, additional, Stuckey, Thomas, additional, Suarez, Jose, additional, Tauth, Jeffrey, additional, Temizer, Dogan, additional, Vidovich, Mladen, additional, Voeltz, Michele, additional, Waltman, Jonathan, additional, and Wilensky, Michael, additional

Published
2021
Full Text
View/download PDF

35. Abstract 10426: Worse Clinical Outcomes in Patients with Acute Coronary Syndrome and Prior or New Onset Heart Failure: Insights from 47,474 Patients in a Pooled Analysis of Randomized Clinical Trials

Author

Goodwin, Nathan, primary, Clare, Robert M, additional, Wojdyla, Daniel, additional, Harrington, Josephine, additional, Badjatiya, Anish, additional, Udell, Jacob A, additional, Butler, Javed, additional, Januzzi, James L, additional, Parikh, Puja, additional, James, Stefan K, additional, Alexander, John H, additional, Lopes, Renato D, additional, Wallentin, Lars C, additional, Ohman, E Magnus M, additional, Hernandez, Adrian F, additional, and Jones, William S, additional

Published
2021
Full Text
View/download PDF

36. Abstract 9346: Results of a Randomized Study to Understand the Patient Experience of Pain and Satisfaction During Cardiac Catheterization Using an Interval of Time

Author

Mall, Anna E, primary, Girton, Thomas A, additional, Yardley, Kevin, additional, Simpson, Elinore, additional, Ronn, Meghan, additional, Rossman, Paige, additional, McEwen, Tiffany, additional, Ohman, E Magnus M, additional, Jones, Schuyler, additional, and Granger, Bradi B, additional

Published
2021
Full Text
View/download PDF

37. TCT-217 Predictors of Dyspnea in Patients Receiving Ticagrelor After PCI: Insights From the Twilight Trial

Author

Angiolillo, Dominick, primary, Pivato, Carlo Andrea, additional, Cao, Davide, additional, Kunadian, Vijay, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Cohen, David, additional, Collier, Timothy, additional, Dudek, Dariusz, additional, Gil, Robert, additional, Huber, Kurt, additional, Kornowski, Ran, additional, Mehta, Shamir, additional, Ohman, E. Magnus, additional, Oldroyd, Keith, additional, Sardella, Gennaro, additional, Sharma, Samin, additional, Shlofmitz, Richard, additional, Weisz, Giora, additional, Witzenbichler, Bernhard, additional, Dangas, George, additional, Pocock, Stuart, additional, and Mehran, Roxana, additional

Published
2021
Full Text
View/download PDF

38. TCT-118 Propensity-Adjusted Population-Based Analysis of Impella in Patients Undergoing High-Risk PCI From a Large-Scale Claims Dataset

Author

Lansky, Alexandra, primary, Tirziu, Daniela, additional, Pietras, Cody, additional, Moses, Jeffrey, additional, Ohman, E. Magnus, additional, O'Neill, William, additional, Grines, Cindy, additional, Needham, Keith, additional, Ekono, Mercedes, additional, Gregory, David, additional, and Parise, Helen, additional

Published
2021
Full Text
View/download PDF

40. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

Author

Escaned, Javier, primary, Cao, Davide, additional, Baber, Usman, additional, Nicolas, Johny, additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Dangas, George, additional, Angiolillo, Dominick J, additional, Briguori, Carlo, additional, Cohen, David J, additional, Collier, Timothy, additional, Dudek, Dariusz, additional, Gibson, Michael, additional, Gil, Robert, additional, Huber, Kurt, additional, Kaul, Upendra, additional, Kornowski, Ran, additional, Krucoff, Mitchell W, additional, Kunadian, Vijay, additional, Mehta, Shamir, additional, Moliterno, David J, additional, Ohman, E Magnus, additional, Oldroyd, Keith G, additional, Sardella, Gennaro, additional, Sharma, Samin K, additional, Shlofmitz, Richard, additional, Weisz, Giora, additional, Witzenbichler, Bernhard, additional, Pocock, Stuart, additional, and Mehran, Roxana, additional

Published
2021
Full Text
View/download PDF

41. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry

Author

Picard, Fabien, primary, Bhatt, Deepak L., additional, Ducrocq, Grégory, additional, Ohman, E. Magnus, additional, Goto, Shinya, additional, Eagle, Kim A., additional, Wilson, Peter W.F., additional, Smith, Sidney C., additional, Elbez, Yedid, additional, and Steg, Philippe Gabriel, additional

Published
2021
Full Text
View/download PDF

42. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention

Author

Vogel, Birgit, primary, Baber, Usman, additional, Cohen, David J., additional, Sartori, Samantha, additional, Sharma, Samin K., additional, Angiolillo, Dominick J., additional, Farhan, Serdar, additional, Goel, Ridhima, additional, Zhang, Zhongjie, additional, Briguori, Carlo, additional, Collier, Timothy, additional, Dangas, George, additional, Dudek, Dariusz, additional, Escaned, Javier, additional, Gil, Robert, additional, Han, Ya-ling, additional, Kaul, Upendra, additional, Kornowski, Ran, additional, Krucoff, Mitchell W., additional, Kunadian, Vijay, additional, Mehta, Shamir R., additional, Moliterno, David, additional, Ohman, E. Magnus, additional, Sardella, Gennaro, additional, Witzenbichler, Bernhard, additional, Gibson, C. Michael, additional, Pocock, Stuart, additional, Huber, Kurt, additional, and Mehran, Roxana, additional

Published
2021
Full Text
View/download PDF

44. Contributors

Author

Abbara, Suhny, Agarwal, Richa, Agha, Ali M., Aguilar, David, Akhrass, Rami, Rifai, Mahmoud Al, Awtry, Eric, Bakaeen, Faisal G., Balady, Gary J., Barshes, Neal, Beauchesne, Luc M., Berman, Jeffrey S., Bernard, Sheilah, Birnbaum, Gilad, Birnbaum, Yochai, Boccalandro, Fernando, Boone, Michael, Boone, Stephen, Borgaonkar, Sanket, Bozkurt, Biykem, Canan, Arzu, Casteel, Kelly N., Chen, Tiffany, Cooper, Leslie T., Jr., Cronin, Edmond M., Dangas, George D., Dave, Amish S., Denktas, Ali E., Eagle, Kim A., Faber, Lothar, Fedson, Savitri, Feinstein, Matthew J., Felker, G. Michael, Fenton, James J., Field, Michael E., Flamm, Scott D., Fleisher, Lee A., Flink, Laura, Fudim, Marat, Ganapathi, Sanjay, Gayle, Kathryn A., Gerhard-Herman, Marie, Graziani, Casey, Grines, Cindy, Gupta, Aakriti, Habib, Gabriel B., Sr., Hamzeh, Ihab, Harikrishnan, Sivadasanpillai, Heresi, Gustavo A., Hinohara, Tomoya T., Hoit, Brian D., Huntley, Geoffrey D., Hussain, Aliza, Janus, Scott E., Jia, Xiaoming, Jneid, Hani, Joglar, Jose A., Kent, Thomas A., Khalid, Umair, Kohnstamm, Sarah, Kondamudi, Nitin, Krittanawong, Chayakrit, Kroll, Michael H., Lange, Richard A., Levine, Glenn N., Litvak, Paul, Liu, Jing, Lyle, Melissa A., Maddox, Thomas, Mahar, Jamal H., Mangione, Salvatore, Marr, Rita, Martini, Sharyl R., McCord, Jim, Mehran, Roxana, Mendes, Lisa A., Merli, Geno J., Mir, Hassan, Misra, Arunima, Nair, Ajith, Nambi, Vijay, Ngeno, G. Titus, Nkomo, Vuyisile T., Ohman, E. Magnus, Palaskas, Nicolas L., Pandey, Ambarish, Pandey, Shivda, Pandit, Lavannya M., Parekh, Maria A., Peacock, W. Frank, Phillips, Lawrence, Pickett, June K., Pipe, Andrew, Prenner, Stuart B., Rajiah, Prabhakar, Rattanawong, Pattara, Reich, Heidi, Roselli, Eric E., Scholtz, Smita, Schurmann, Paul, Senguttuvan, Nagendra Boopathy, Shah, Hirak, Shah, Nishant R., Shah, Sanjiv J., Shah, Tina, Shaib, Fidaa, Shen, Win K., Shreyder, Katherine, Singh, Mohita, Singh-Kucukarslan, Gulmohar, Spelde, Audrey E., Spinler, Sarah A., Sudhakar, Deepthi, Suffredini, John M., Tamara, Luis A., Thaden, Jeremy J., Thavendiranathan, Paaladinesh, Thompson, Kara A., Valderrábano, Miguel, Vargo, Patrick R., Vidula, Mahesh K., Vijayakumar, Shilpa, Virani, Salim S., and Vogel, Birgit

Published
2023
Full Text
View/download PDF

46. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of...

Author

Gibson, C Michael, Mack, Michael J, Lee, Victoria T, Schneider, David J, Sellke, Frank W, Ohman, E Magnus, Thourani, Vinod H, Doros, Gheorghe, Kroger, Hans, Cutlip, Donald E, and Deliargyris, Efthymios N

Abstract

Background: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate the effectiveness and safety of the DrugSorb-ATR hemoadsorption device for the intraoperative removal of ticagrelor to reduce postoperative bleeding in the above patient population. The Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial is a multi-center, double-blind, randomized, controlled trial enrolling patients who require cardiothoracic surgery on cardiopulmonary bypass (CPB) within 48 hours of last ticagrelor dose.Methods: Subjects will be randomized 1:1 to receive either the DrugSorb-ATR device or an identical sham device during CPB. The study will enroll up to 120 subjects at 20 U.S centers, and the primary outcome is the composite of fatal perioperative bleeding, moderate/severe/massive bleeding according to the Universal Definition of Perioperative Bleeding in Cardiac Surgery (UDPB), and 24 hours chest tube drainage. The components of the composite are hierarchically ranked according to clinical significance and the primary analysis will utilize the Win Ratio method. Percent change in ticagrelor levels before and after CPB (drug removal) will be the key secondary endpoint. An independent Clinical Events Committee will adjudicate all clinical endpoints including safety endpoints relating to postoperative thrombotic events. Subjects will be followed through 30 days after the index operation.Conclusions: The results from STAR-T, if positive, will potentially support FDA market approval for DrugSorb-ATR, and provide a solution to an important unmet clinical need. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. Predictors of outcomes after PCI with incomplete revascularization: Impact of CTO and LAD vessel.

Author

Kuno T, Weisz G, Généreux P, Claessen BE, Shechter M, Alexander KP, James SK, Ohman EM, Dressler O, Mehran R, Ben-Yehuda O, and Stone GW

Abstract

Background: Incomplete revascularization (ICR) after percutaneous coronary intervention (PCI) is associated with mortality and morbidity., Aim: We sought to investigate whether ICR in the left anterior descending artery (LAD) is worse than ICR of the right coronary artery (RCA) or left circumflex artery (LCX); and whether ICR in patients with a chronic total occlusion (CTO) is worse than in those without., Methods: In the RIVER-PCI trial, 2651 patients with ICR after PCI were randomly assigned to ranolazine or placebo. Angiograms were assessed at an independent core laboratory in 2501 patients (94.3%). The primary endpoint was the composite of ischemia-driven revascularization or hospitalization., Results: A total of 1664 patients (66.5%) had ICR involving the LAD, whereas 837 (33.5%) had ICR limited to the RCA or LCX. At median follow-up of 643 days, the primary endpoint occurred in 26.9% versus 26.5% of patients (adjusted HR [aHR]: 1.03, 95% confidence interval [CI]: 0.88-1.21). A nonrecanalized CTO was present in 854 patients (34.1%) with ICR after PCI. The primary endpoint occurred in 28.6% versus 25.9% of ICR patients with versus without a CTO (aHR: 1.10, 95% CI: 0.94-1.29). However, patients with a CTO had higher rates of ischemia-driven hospitalization without revascularization (aHR: 1.27, 95% CI: 1.04-1.56), heart failure hospitalization (aHR: 2.69, 95% CI: 1.61-4.59) and myocardial infarction (aHR: 1.46, 95% CI: 1.11-1.92) compared with those without., Conclusions: The 2-year prognosis was similar in post-PCI patients with ICR whether the LAD was versus was not involved. ICR patients with a CTO had more frequent hospitalizations for ischemia and myocardial infarctions compared with those without., (© 2024 Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

49. Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y 12 Inhibitor Therapy: The CAMEO Registry.

Author

Rymer J, Alhanti B, Kemp S, Bhatt DL, Kochar A, Angiolillo DJ, Diaz M, Garratt KN, Wimmer NJ, Waksman R, Kirtane AJ, Ang L, Bach R, Barker C, Jenkins R, Basir MB, Sullivan A, El-Sabae H, Brothers L, Ohman EM, Jones WS, Washam JB, and Wang TY

Abstract

Background: Little is known about the bleeding risk associated with cangrelor use in patients with myocardial infarction (MI) who are exposed to an oral P2Y 12 inhibitor before coronary angiography., Methods: Cangrelor in Acute MI: Effectiveness and Outcomes (CAMEO) is an observational registry studying platelet inhibition for patients with MI. Upstream oral P2Y 12 inhibition was defined as receipt of an oral P2Y 12 inhibitor within 24 hours before hospitalization or in-hospital before angiography. Among cangrelor-treated patients, we compared bleeding after cangrelor use through 7 days postdischarge between patients with and without upstream oral P2Y 12 inhibitor exposure., Results: Among 1802 cangrelor-treated patients with MI, 385 (21.4%) received upstream oral P2Y 12 inhibitor treatment. Of these, 101 patients (33.8%) started cangrelor within 1 hour, 103 (34.4%) between 1 and 3 hours, and 95 (31.8%), >3 hours after in-hospital oral P2Y 12 inhibitor administration; the remaining received an oral P2Y 12 inhibitor before hospitalization. There was no statistically significant difference in rates of bleeding among cangrelor-treated patients with and without upstream oral P2Y 12 inhibitor exposure (6.5% vs 8.8%; adjusted odds ratio [OR], 0.62; 95% CI, 0.38-1.01). Bleeding was observed in 5.0%, 10.7%, and 3.2% of patients treated with cangrelor <1, 1 to 3, and >3 hours after the last oral PY 12 inhibitor dose, respectively; bleeding rates were not statistically different between groups (1-3 hours vs <1 hour: adjusted OR, 2.70; 95% CI, 0.87-8.32; >3 hours vs <1 hour: adjusted OR, 0.65; 95% CI, 0.15-2.85)., Conclusions: Bleeding risk was not observed to be significantly higher after cangrelor treatment in patients with and without upstream oral P2Y12 inhibitor exposure., (© 2023 The Author(s).)

Published
2023
Full Text
View/download PDF

50. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.

Author

Dehghani P, Cao D, Baber U, Nicolas J, Sartori S, Pivato CA, Zhang Z, Dangas G, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dudek D, Gibson M, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta S, Moliterno DJ, Ohman EM, Escaned J, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, and Mehran R

Subjects
Aspirin adverse effects, Drug Therapy, Combination, Hemorrhage chemically induced, Hemorrhage epidemiology, Humans, Myocardial Infarction epidemiology, Stroke epidemiology, Diabetes Mellitus drug therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, Platelet Aggregation Inhibitors adverse effects, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic therapy, Ticagrelor adverse effects
Abstract

Aims: We aimed to evaluate the treatment effects of ticagrelor monotherapy in the very high risk cohort of patients with concomitant diabetes mellitus (DM) and chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI)., Methods and Results: In the TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention) trial, after 3-month dual antiplatelet therapy with ticagrelor and aspirin post-PCI, event-free patients were randomized to either aspirin or placebo in addition to ticagrelor for 12 months. Those with available information on DM and CKD status were included in this subanalysis and were stratified by the presence or absence of either condition: 3391 (54.1%) had neither DM nor CKD (DM-/CKD-), 1822 (29.0%) had DM only (DM+/CKD-), 561 (8.9%) had CKD only (DM-/CKD+), and 8.0% had both DM and CKD (DM+/CKD+). The incidence of the primary endpoint of Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding did not differ according to DM/CKD status (P-trend = 0.13), but there was a significant increase in BARC 3 or 5 bleeding (P-trend &lt; 0.001) as well as the key secondary endpoint of death, myocardial infarction, or stroke (P-trend &lt; 0.001). Ticagrelor plus placebo reduced bleeding events compared with ticagrelor plus aspirin across all four groups, including DM+/CKD+ patients with respect to BARC 2-5 [4.5% vs. 8.7%; hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.24-1.01] as well as BARC 3-5 (0.8% vs. 5.3%; HR 0.15, 95% CI 0.03-0.53) bleeding, with no evidence of heterogeneity. The risk of death, myocardial infarction, or stroke was similar between treatment arms across all groups., Conclusion: Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results